This content is restricted.
Brief
On "12/11/2024", the "French National Agency for the Safety of Medicines and Health Products (ANSM)" issued an update regarding "ANSM publishes its haemovigilance report for the year 2023". The report shows that most adverse effects, among donors and recipients, are non-severe and comparable to previous years. No signal was identified in 2023. Key aspects of the haemovigilance surveillance include monitoring EIGD, IPD, transfusion chain incidents, and EIR in the blood donation chain.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
